On October 24, 2012, ARIAD Pharmaceuticals, Inc. ("Company") issued a press release announcing that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for accelerated review of ARIAD's investigational BCR-ABL inhibitor, ponatinib, in patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). The FDA also has granted ARIAD's request for Priority Review, which is given to investigational medicines that have the potential for providing significant improvement in the treatment, prevention, or diagnosis of a disease. The FDA has established an action date of March 27, 2013 under the Prescription Drug User Fee Act (PDUFA).

A copy of the press release is being filed herewith as Exhibit 99.1 and the information contained therein is incorporated by reference into this Current Report on Form 8-K.

(d) The following exhibit is filed with this report:

Exhibit
Number  Description

99.1    Press Release dated October 24, 2012.